Immune intervention reduces beta-cell death in type 1 diabetes

February 26, 2013
Immune intervention reduces beta-cell death in type 1 diabetes
Patients recently diagnosed with type 1 diabetes have greater death of pancreatic β-cells compared with patients with long-standing diabetes, which can be reduced by treatment with teplizumab, according to a study published online Feb. 19 in Diabetes.

(HealthDay)—Patients recently diagnosed with type 1 diabetes have greater death of pancreatic β-cells compared with patients with long-standing diabetes, which can be reduced by treatment with teplizumab, according to a study published online Feb. 19 in Diabetes.

Jasmin Lebastchi, from the Yale University School of Medicine in New Haven, Conn., and colleagues compared β- in 43 patients recently diagnosed with , 31 individuals without diabetes, and 37 patients with type 1 diabetes treated with teplizumab or placebo. β-cell death was determined by measuring relative levels of unmethylated INS DNA in serum.

The researchers found that, compared with individuals without diabetes, patients with recent-onset diabetes had higher rates of β-cell death, while patients with long-standing diabetes had lower levels of β-cell death. After treatment of recent-onset with teplizumab, β-cell death was significantly reduced and β-cell function was significantly better preserved.

"Improvement in C-peptide responses with immune intervention is associated with decreased β-cell death," Lebastchi and colleagues write.

Several authors have for teplizumab and/or the assay of unmethylated insulin DNA and are on the scientific advisory board of Islet Sciences.

Explore further: Cancer prevalence higher with long duration of diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Glucose levels at admission predict death in pneumonia

May 30, 2012

(HealthDay) -- For patients with community-acquired pneumonia without preexisting diabetes, serum glucose levels at admission are predictive of death at 28 and 90 days, according to a study published online May 29 in BMJ.

Turmeric component reduces type 2 diabetes incidence

July 12, 2012

(HealthDay) -- A component of turmeric -- curcumin -- reduces the incidence of type 2 diabetes and improves β-cell function in adults with prediabetes, according to a study published online July 6 in Diabetes Care.

Recommended for you

Low-carb diet may aid your metabolism

December 2, 2016

(HealthDay)—Eating low-carbohydrate meals may lead to healthy changes in a woman's metabolism that don't occur when consuming higher-carbohydrate meals, a small study suggests.

Research shows nerve growth protein controls blood sugar

November 14, 2016

Research led by a Johns Hopkins University biologist demonstrates the workings of a biochemical pathway that helps control glucose in the bloodstream, a development that could potentially lead to treatments for diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.